In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...

and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema ...

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases ... age-related macular degeneration and diabetic macular edema. Upon successful ...

However, consistent diabetes management provides the best defense against this complication. Regular monitoring helps detect early signs of macular edema ... prevents retinal cells from receiving ...

The macular cube 512 × 128 scan protocol was used to acquire all 128 OCT B-scans that covered an area of 6 × 6 mm and were 2 mm in length centered on the fovea. A mean retinal thickness (RT ...

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME ... targets the drug to the choroid and retina by binding transferrin receptors on endothelial ...

When the blood glucose is higher than normal, it is known to damage nerve cells and blood vessels in the body ... eye due to abnormal blood vessels growing out of the retina. Diabetic macular edema: ...

As opposed to general monitoring of diabetes, which can be performed easily (blood ... primary open angle glaucoma; RGC, retinal ganglion cell(s); RNFL, retinal nerve fiber layer; ROP, retinopathy of ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The global diabetic macular edema market is on a steady growth trajectory ... citing good results from phase III trials on Vabysmo for retinal vein occlusion. Segmentation by drug includes anti-VEGF ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...